

# Konstantinos H Katsanos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3962793/publications.pdf>

Version: 2024-02-01

61  
papers

2,014  
citations

304743

22  
h-index

254184

43  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and safety of tofacitinib in ulcerative colitis: Done is better than perfect. <i>Digestive and Liver Disease</i> , 2022, 54, 151-153.	0.9	0
2	Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2868-2875.e1.	4.4	9
3	Medical, Endoscopic and Surgical Management of Strictureing Crohn's Disease: Current Clinical Practice. <i>Journal of Clinical Medicine</i> , 2022, 11, 2366.	2.4	4
4	Postoperative mortality after surgery for inflammatory bowel disease: The myth of Apollo and Artemis. <i>Digestive and Liver Disease</i> , 2021, 53, 52-53.	0.9	0
5	Current noninvasive modalities in Crohn's disease monitoring. <i>Annals of Gastroenterology</i> , 2021, 34, 770-780.	0.6	1
6	Immunohistochemical study of adhesion molecules in irritable bowel syndrome: A comparison to inflammatory bowel diseases. <i>Advanced Biomedical Research</i> , 2021, 10, 21.	0.5	2
7	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	1.7	6
8	Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know?. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 466-473.	1.2	9
9	The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2021, 35, 1-7.	0.6	2
10	Ocular manifestations in celiac disease: an overview. <i>International Ophthalmology</i> , 2020, 40, 1049-1054.	1.4	17
11	The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up: an Epi-IBD study. <i>United European Gastroenterology Journal</i> , 2020, 8, 949-960.	3.8	17
12	Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3533.	2.4	29
13	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 454-464.	8.1	76
14	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	1.8	19
15	Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease. <i>Intestinal Research</i> , 2020, 18, 115-120.	2.6	24
16	Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. <i>Cells</i> , 2019, 8, 817.	4.1	14
17	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	2.5	111
18	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. <i>Clinical Immunology</i> , 2019, 206, 9-14.	3.2	63

#	ARTICLE	IF	CITATIONS
19	Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Journal of Clinical Medicine Research</i> , 2019, 11, 81-88.	1.2	7
20	ATG16L1 T300A polymorphism is associated with Crohn's disease in a Northwest Greek cohort, but ECM1 T130M and G290S polymorphisms are not associated with ulcerative colitis. <i>Annals of Gastroenterology</i> , 2019, 33, 38-44.	0.6	4
21	Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. <i>Annals of Gastroenterology</i> , 2019, 32, 168-173.	0.6	3
22	Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2019, 11, 424-426.	1.2	0
23	Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 465-466.	1.9	0
24	Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. <i>Annals of Gastroenterology</i> , 2018, 31, 659-669.	0.6	43
25	Role of bile acids in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2018, 31, 266-272.	0.6	53
26	Management of Paediatric Ulcerative Colitis, Part 1. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 67, 257-291.	1.8	292
27	Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1272-1273.	1.9	0
28	Alcohol and narcotics use in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2018, 31, 649-658.	0.6	22
29	Minimally Invasive Surgical Approaches for Pancreatic Adenocarcinoma: Recent Trends. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 129-134.	1.3	10
30	Histological healing beyond endoscopic healing in ulcerative colitis: Shall we target the "ultra-deep" remission?. <i>Digestive and Liver Disease</i> , 2017, 49, 1332-1333.	0.9	3
31	Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2017, 264, 254-259.	3.6	73
32	Current and future biomarkers in colorectal cancer. <i>Annals of Gastroenterology</i> , 2017, 30, 613-621.	0.6	88
33	Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 256-257.	1.3	6
34	Segmental colitis associated with diverticulosis: is it the coexistence of colonic diverticulosis and inflammatory bowel disease?. <i>Annals of Gastroenterology</i> , 2017, 30, 257-261.	0.6	37
35	Pseudopolyps in inflammatory bowel diseases: Have we learned enough?. <i>World Journal of Gastroenterology</i> , 2017, 23, 1541.	3.3	37
36	<i>Strongyloides stercoralis</i> infection: an "exotic" cause of chronic diarrhea. <i>Annals of Gastroenterology</i> , 2017, 30, 467.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1426-1432.e1.	4.4	39
38	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1385-1394.	1.3	115
39	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	1.3	114
40	Implementation of the simple endoscopic activity score in crohn's disease. <i>Saudi Journal of Gastroenterology</i> , 2016, 22, 183.	1.1	46
41	Fast-track drug approval in inflammatory bowel diseases. <i>Annals of Gastroenterology</i> , 2016, 29, 439-444.	0.6	4
42	Inflammatory Bowel Disease and Sexual Function in Male and Female Patients: An Update on Evidence in the Past Ten Years. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1160-1168.	1.3	36
43	European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 945-965.	1.3	328
44	Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. <i>World Journal of Gastrointestinal Endoscopy</i> , 2015, 7, 643.	1.2	17
45	Pharmacogenetics of inflammatory bowel disease. <i>Pharmacogenomics</i> , 2014, 15, 2049-2062.	1.3	10
46	Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 135-139.	0.9	37
47	Changes of serum adhesion molecules and cytokines in post-ERCP pancreatitis. <i>Clinical Biochemistry</i> , 2014, 47, 1245-1249.	1.9	3
48	Adult-onset Still's disease preceding Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e93-e98.	1.3	10
49	Coexistence of Crohn's disease in a patient with systemic lupus erythematosus. <i>Rheumatology International</i> , 2013, 33, 2145-2148.	3.0	8
50	Inflammatory bowel disease and lupus: A systematic review of the literature. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 735-742.	1.3	52
51	Balloon dilatation of ileo-colonic anastomosis in Crohn's disease. <i>Annals of Gastroenterology</i> , 2012, 25, 181.	0.6	0
52	Eosinophilic-Crohn overlap colitis and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 256-261.	1.3	24
53	Silent ulcerative colitis adjacent to a regular sigmoid adenocarcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 957-960.	1.6	4
54	Isolated rectal ulcer. <i>Annals of Gastroenterology</i> , 2011, 24, 121.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Nonsteroidal anti-inflammatory drug-induced acute ulcers in the colon. <i>Annals of Gastroenterology</i> , 2011, 24, 320.	0.6	3
56	Non-toxic megacolon due to transverse and sigmoid colon volvulus in a patient with ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 38-41.	1.3	12
57	Sjogren's syndrome in a patient with ulcerative colitis and primary sclerosing cholangitis: Case report and review of the literature. <i>Journal of Crohn's and Colitis</i> , 2009, 3, 200-203.	1.3	15
58	Thrombin promotes arteriogenesis and hemodynamic recovery in a rabbit hindlimb ischemia model. <i>Journal of Vascular Surgery</i> , 2009, 49, 1000-1012.	1.1	17
59	Phantom cytomegalovirus infection in vasculitis patients: what it means and what to do. <i>Rheumatology International</i> , 2005, 25, 631-632.	3.0	4
60	High CA 19-9 levels in benign biliary tract diseases. <i>European Journal of Internal Medicine</i> , 2002, 13, 132-135.	2.2	31
61	The true value of serum elastase-1 in endoscopic retrograde cholangiopancreatography (ERCP). <i>European Journal of Internal Medicine</i> , 2002, 13, 329-335.	2.2	1